Michael J. Schmitt

Array ( [id] => 15468415 [patent_doc_number] => 10550069 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-04 [patent_title] => L-ornithine phenyl acetate and methods of making thereof [patent_app_type] => utility [patent_app_number] => 16/037655 [patent_app_country] => US [patent_app_date] => 2018-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 21662 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16037655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13536523 [patent_doc_number] => 20180319805 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/036207 [patent_app_country] => US [patent_app_date] => 2018-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37101 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16036207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363999 [patent_doc_number] => 20200017764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => REAGENT AND KIT FOR PERFORMING CHEMILUMINESCENT REACTION [patent_app_type] => utility [patent_app_number] => 16/034821 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3523 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 313 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16034821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13551735 [patent_doc_number] => 20180327415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-15 [patent_title] => CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/035449 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16035449 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17133683 [patent_doc_number] => 11135218 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Synthetic lethality and the treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/025835 [patent_app_country] => US [patent_app_date] => 2018-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 6 [patent_no_of_words] => 9821 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16025835 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504473 [patent_doc_number] => 20180303779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => Methods of Reducing Risk of Cardiovascular Disease [patent_app_type] => utility [patent_app_number] => 16/024288 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16024288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504619 [patent_doc_number] => 20180303852 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => Method For Making Bismuth Containing Liquid Pharmaceutical Suspensions [patent_app_type] => utility [patent_app_number] => 16/021502 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16021502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15814087 [patent_doc_number] => 10632200 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-28 [patent_title] => Bismuth containing liquid pharmaceutical suspensions [patent_app_type] => utility [patent_app_number] => 16/021089 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 8394 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16021089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13478897 [patent_doc_number] => 20180290991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-11 [patent_title] => Composition of 1,3,4-selenadiazole containing compounds with pharmacological activity [patent_app_type] => utility [patent_app_number] => 16/009106 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4096 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16009106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13603885 [patent_doc_number] => 20180353491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => METHODS OF TREATING BRAIN TUMORS USING COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/006234 [patent_app_country] => US [patent_app_date] => 2018-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16006234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15800955 [patent_doc_number] => 20200123620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => MiRNA-574-5p AS A BIOMARKER FOR STRATIFICATION OF PROSTAGLANDIN E-DEPENDENT TUMORS [patent_app_type] => utility [patent_app_number] => 16/621683 [patent_app_country] => US [patent_app_date] => 2018-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16621683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15932007 [patent_doc_number] => 20200157637 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => TARGETING OF ANAPLASTIC LYMPHOMA KINASE IN SQUAMOUS CELL CARCINOMA [patent_app_type] => utility [patent_app_number] => 16/615234 [patent_app_country] => US [patent_app_date] => 2018-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17923920 [patent_doc_number] => 11467160 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Method of therapy selection for patient suffering from glioblastoma [patent_app_type] => utility [patent_app_number] => 16/612153 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 10406 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386277 [patent_doc_number] => 20180244680 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/968976 [patent_app_country] => US [patent_app_date] => 2018-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28293 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15968976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13504481 [patent_doc_number] => 20180303783 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING RETINOPATHY [patent_app_type] => utility [patent_app_number] => 15/958598 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3120 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15958598 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17726529 [patent_doc_number] => 11382894 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-12 [patent_title] => Pharmaceutical compositions for use in the treatment of cardiovascular calcification [patent_app_type] => utility [patent_app_number] => 16/498807 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 4427 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16075571 [patent_doc_number] => 20200191772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => COMBINED ANTICANCER AGENT SENSITIVITY DETERMINATION MARKER [patent_app_type] => utility [patent_app_number] => 16/498940 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13328459 [patent_doc_number] => 20180215767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/938040 [patent_app_country] => US [patent_app_date] => 2018-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15938040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13507529 [patent_doc_number] => 20180305307 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/926657 [patent_app_country] => US [patent_app_date] => 2018-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -101 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15926657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13424859 [patent_doc_number] => 20180263972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE [patent_app_type] => utility [patent_app_number] => 15/922329 [patent_app_country] => US [patent_app_date] => 2018-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15922329 [rel_patent_id] =>[rel_patent_doc_number] =>)